

# **SYNERGIES WORKING GROUP ERA4HEALTH 2024**

ERA4Health Partnership

WP8

Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement N°: 101095426. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.



**Co-funded by  
the European Union**



# Synergies Working Group 2024 WP8



## D8.1 – D1.3.2 Synergies Working Group Era4Health 2024

## GLOSSARY / LIST OF ACRONYMS

AWP: Annual Work Plan

B1MG: Beyond 1 Million Genomes Project

BBMRI: Biobanking and Biomolecular Resources Research Infrastructure

BE READY: Building a European strategic REsearch and innovation Area in Direct sYnergy with EU and International Initiatives for Pandemic Preparedness

Col: Conflict of Interest

COMET: Core Outcome Measures in Effectiveness Trials

conect4children: Collaborative Network for European Clinical Trials for Children

CRIGH: Clinical Research Initiative for Global Health

CSA IC2PerMed: Integrating China in the International Consortium for Personalised Medicine

CSA SINO-EU PerMed: Cooperation between China and Europe in Personalised Medicine

CTTI: Clinical Trials Transformation Initiative

E4H: ERA4Health

EATRIS: European Infrastructure for Translational Medicine

ECHOS: Establishing of Cancer Mission Hubs

ECRAID: European Clinical Research Alliance on Infectious Diseases

ECRIN: European Clinical Research Infrastructure Network

EDCTP: European & Developing Countries Clinical Trials Partnership

EIT Health-KIC: European Institute of Innovation and Technology Health - Knowledge and Innovation Community

EJP RD: European Joint Programme on Rare Diseases

ELIXIR: Life-Science Infrastructure for Biological Information

EMA: European Medicines Agency

EP PerMed: European Partnership for Personalised Medicine

EOSC: European Open Science Cloud

ERA: European Research Area

ERA PerMed: ERA-Net Cofund on Personalised Medicine

ERA-Net Neuron: European Research Area Network of European Funding for Neurosciences Research

ERDF: European Regional Development Fund

ERINHA: European Research Infrastructure on Highly Pathogenic Agents

ESFRI: European Strategy Forum on Research Infrastructures

ESF+: European Social Fund Plus

EU: European Union

EU4Health Programme: European Union for Health Programme

EUHA: European University Hospital Alliance  
EUP AH&W: EU Partnership Animal Health and Welfare  
EU-Africa PerMed Project: Building links between Europe and Africa in Personalised Medicine  
EU-AMRI: European Alliance of Medical Research Infrastructures  
EU-Openscreen-ERIC: Not-for-profit European Research Infrastructure Consortium (ERIC) for chemical biology and early drug discovery  
EU-PEARL: EU Patient-centric clinical trial Platforms  
EuroBioimaging ERIC: European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences  
FACCEJPI: Joint Programming Initiative on Agriculture, Food Security and Climate Change  
FutureFoodS: European Partnership for a Sustainable Future of Food Systems  
GA: Grant Agreement  
GACD: Global Alliance for Chronic Diseases  
ICPerMed: International Consortium for Personalised Medicine  
IHI: Innovative Health Initiative  
IICS: Investigator Initiated Clinical Studies  
INFRAFRONTIER: European Research Infrastructure for Modelling Human Diseases  
IRDiRC: International Rare Diseases Research Consortium  
JPI AMR: Joint Programming Initiative on Antimicrobial Resistance  
JPI HDHL: Joint Programming Initiative a Healthy Diet for a Healthy Life  
JPND Research: Joint Programme - Neurodegenerative Disease Research  
JTC: Joint Transnational Calls  
MIRRI: Microbial Resource Research Infrastructure  
NordForsk: Organisation under the Nordic Council of Ministers that facilitates and provides funding for Nordic research cooperation  
OH AMR: Candidate European Partnership One Health Antimicrobial Resistance  
PARC: Partnership for the Assessment of Risks from Chemicals  
PRO-Ethics: Participatory Real Life Experiments in Research and Innovation Funding Organisations on Ethics.  
PRUDENT: Prioritization, incentives and Resource use for sUstainable DENTistry  
REMiDi4ALL: Repurposing of Medicines for All  
SBEP: Sustainable Blue Economy Partnership  
SHARE ERIC: Survey of Health Ageing and Retirement in Europe  
THCS: Transforming Health Care Systems Partnership  
The global health network: Platform and community of health workers and researchers  
TMRP: MRC-NIHR Trials Methodology Research Partnership  
ToR: Terms of Reference  
TRANSCAN: Sustained collaboration of national and regional programmes in cancer research  
Trials@Home: Centre of Excellence for Decentralised Clinical Trials  
SWG: Synergies Working Group  
SRIA: Strategic Research and Innovation Agenda

## Water4All: Partnership Water security for the planet WP: Work Package

### Updates 2024:

- List of acronyms pages: 2-4)
- Tables pages: 6-8)
- INITIATIVES RELATED TO HEALTH:  
Inclusion of PRUDENT and ECHOS representatives (pages: 29 -30)
- INITIATIVES RELATED TO OTHER FIELDS THAN HEALTH
- Inclusion of ProEthics representative (pages: 37 )
- INITIATIVES RELATED TO CLINICAL STUDIES AND RESEARCH INFRASTRUCTURES Inclusion/Update of REMIDI4ALL, MRC-NIHR Trials Methodology Research Partnership (TMRP) and CRIGH representatives. Pages: 47-50)

## EXECUTIVE SUMMARY

This document serves as an updated presentation of the Synergies Working Group (SWG) established by ERA4Health in 2023. It highlights the group's objectives and methodology while incorporating the latest updates and additions for 2024.

### 2. 2024 Updates

The following updates have been included in this version:

#### Initiatives Related to Health

- Addition of representatives for **PRUDENT** and **ECHOS** (pages 29-30).

#### Initiatives Related to Other Fields than Health

- Inclusion of the **ProEthics** representative (pages 37).

#### Initiatives Related to Clinical Studies and Research Infrastructures

- Inclusion/Update of representatives for **REMEDI4ALL**, **MRC-NIHR Trials Methodology Research Partnership (TMRP)**, and **CRIGH** (pages 47-50).

These updates ensure the SWG remains a dynamic and comprehensive platform for fostering synergies across European and international initiatives, supporting the overarching goals of ERA4Health to strengthen collaboration, coherence, and impact within the research and innovation ecosystem.

Table 1: List of members of the SWG

Ref*	Initiative	Contact Name	Invitation sent (date)	Acceptance (date)	Profile form / Statement of Acceptance sent (date)	Profile form / Statement of Acceptance received (date)
<b>1) INITIATIVES IN THE FIELD OF HEALTH</b>						
1.1	JPI-HDHL	Jessie Doppler	28/02/2023	28/02/2023	28/02/2023	09/03/2023
1.2	Horizon Europe Cluster 1	Greg Owsianik	17/04/2023	19/04/2023	24/04/2023	Pending
1.3	EU4Health	María José González de Suso	14/03/2023	17/04/2023	17/04/2023	27/04/2023
1.4	TRANSCAN-3	Inés Rey	10/04/2023	10/04/2023	10/04/2023	10/04/2023
1.5	ERA PerMed	Cristina Nieto	27/02/2023	08/03/2023	08/03/2023	10/04/2023

1.6	EJP RD	Daria Julkowska	28/02/2023	28/02/2023	08/03/2023	09/03/2023
1.7	JPI AMR	Laura Marin	28/02/2023	28/02/2023	08/03/2023	13/03/2023
1.8	IHI	Magali Poinot	29/03/2023	17/04/2023	17/04/2023	18/04/2023
1.9	EP PerMed	Wolfgang Ballensiefen	28/02/2023	02/03/2023	02/03/2023	29/03/2023
1.10	BE READY	Hervé Raoul	21/03/2023	23/03/2023	24/03/2023	30/03/2023
1.11	ERA-Net NEURON	Hella Lichtenberg	28/02/2023	16/03/2023	16/03/2023	29/03/2023
1.12	JPND	Philippe Amouyel	12/04/2023	13/04/2023	14/04/2023	02/05/2023
1.13	OH AMR	Laura Marin	28/02/2023	28/02/2023	08/03/2023	13/03/2023
1.14	ICPerMed	Wolfgang Ballensiefen	28/02/2023	02/03/2023	02/03/2023	29/03/2023
1.15	IRDiRC	Daria Julkowska	28/02/2023	28/02/2023	08/03/2023	09/03/2023
1.16	EU-Africa PerMed Project	Erika Sela	08/03/2023	08/03/2023	09/03/2023	09/03/2023
1.17	CSA IC2PerMed	Stefania Boccia	08/03/2023	08/03/2023	08/03/2023	08/03/2023
1.18	THCS	Ciara Ciccarelli & Francesca Turco	25/04/2023	25/04/2023	25/04/2023	02/05/2023
1.19	FLASH	Paolo Pertile	28/04/2023	29/04/2023	02/05/2023	03/05/2023
1.20	PRUDENT	Stefan Listl	19/07/2023	19/07/2023	19/07/2023	19/07/2023
1.21	ECHOS	Hugo Soares	11/01/2024	11/01/2024	11/01/2024	11/01/2024
<b>2) INITIATIVES IN OTHER FIELDS THAN HEALTH</b>						
2.1	Water4All	Juliette Arabi	28/02/2023	13/04/2023	14/04/2023	19/04/2023
2.2	FutureFoodS	Gilles Feron	17/04/2023	17/04/2023	17/04/2023	21/04/2023
2.3	SBEP	Maurice Heral	28/02/2023	06/03/2023	07/03/2023	Pending
2.4	FACCE JPI	Heather McKhann	28/02/2023	11/04/2023	11/04/2023	Pending
2.5	Animal Health and Welfare	Agnès Roba	28/02/2023	28/02/2023	07/03/2023	13/03/2023



2.6	NordForsk	Kristin Andersen	28/02/2023	06/03/2023	07/03/2023	14/03/2023
2.7	PRO-Ethics	Stefanie Schuerz	19/02/2024	19/02/2024	19/02/2024	19/02/2024
<b>3) INITIATIVES RELATED TO CLINICAL STUDIES AND RESEARCH INFRASTRUCTURES</b>						
3.1	ECRIN	Marta Del Alamo	28/02/2023	02/03/2023	08/03/2023	09/03/2023
3.2	EATRIS	Anton Ussi	08/03/2023	27/03/2023	28/03/2023	31/03/2023
3.3	ESFRI	Dominik Sobczak	03/03/2023	03/03/2023	08/03/2023	10/03/2023
3.4	EUHA	Lynn Seveke	28/02/2023	17/04/2023	17/04/2023	Pending
3.5	Conect4children	Mark Turner	28/02/2023	28/02/2023	08/03/2023	08/03/2023
3.6	MIRRI	Luís Miguel Guimarães Soares	28/02/2023	03/03/2023	07/03/2023	07/03/2023
3.7	ERINHA	Diana Stepanyan	28/02/2023	12/04/2023	07/03/2023	Pending
3.8	EOSC	Ute Günsenheimer	28/02/2023	28/02/2023	07/03/2023	Pending
3.9	Trials@Home	Mira Zuidgeest	08/03/2023	14/04/2023	14/04/2023	11/05/2023
3.10	COMET	Paula Williamson	08/03/2023	08/03/2023	09/03/2023	09/03/2023
3.11	ELIXIR	Andrew Smith	24/04/2023	02/05/2023	02/05/2023	02/05/2023
3.12	Remedi4All	Jilian Harrison	06/08/2024	06/08/2024	06/08/2024	06/08/2024
3.13	MRC-NIHR Trials Methodology Research Partnership (TMRP)	Professor Paula Williamson	01/03/2024	01/03/2024	01/03/2024	01/03/2024
3.14	CRIGH	Nandi Louise Siegfried/Øyvind Melien	08/05/2024	08/05/2024	08/05/2024	08/05/2024

## 1) INITIATIVES IN THE FIELD OF HEALTH

**Reference: 1.1**

**European Initiative: JPI HDHL**

Coordinating research in the area of nutrition, diet, health and physical activity: The Joint Programming Initiative a Healthy Diet for a Healthy Life (JPI HDHL) brings together 20 countries that align research programming and fund new research to prevent or minimise diet-related chronic diseases.

Member of the SWG:



Name and Surname:

**Jessie Doppler**

Organisation:

ZonMw

Brief CV (the entire profile is expected to take up one page):

As the Coordinator of JPI HDHL (Joint Programming Initiative A Healthy Diet for A Health Life) and Senior Program Manager at The Netherlands Health Research and Development Organisation (ZonMw), I specialise in science and policy in the fields of nutrition, health, lifestyle and sustainable food systems. I create connections, implement and foster cooperation in multi-stakeholder collaborative projects, while focusing on external engagement, communications and aligning research and its impact across the European landscape. I am committed to high-level strategic planning in the context of transnational collaborations and translating them from science to policy.

I am a curious and multilingual professional with a background in intercultural communications, international cooperation and business development having gained experience working in France, Austria, the UK, Germany and The Netherlands.

Over the years, I have worked with a wide range of stakeholders spanning across government, NGOs, academia and industry.

**Reference: 1.2**

**European Initiative: Horizon Europe – Cluster 1**

The aims of this cluster include improving and protecting the health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases. Further aims include developing health technologies, mitigating health risks, protecting populations and promoting good health and well-being in general and at work. Finally, this cluster also aims to make public health systems more cost-effective, equitable and sustainable, prevent and tackle poverty-related diseases and support and enable patients' participation and self-management.

**Reference: 1.3**
**European Initiative: EUHealth Programme**


EU4Health is the EU's largest health programme in monetary terms, with a budget of €5.3 billion in current prices. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. EU4Health provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe. The EU4Health programme is a key pillar to the Commission's work to strengthen the European Health Union and contribute to the EU's health priorities. The actions funded under the EU4Health programme pursue 4 goals and 10 specific objectives. EU4Health will also be investing in urgent health priorities: response to COVID-19 pandemic and resilience for cross-border health threats; Europe's Beating Cancer Plan; The Pharmaceutical Strategy for Europe. And other areas: the digitalisation of health systems, antimicrobial resistance, improved vaccination rates.

Member of the SWG:

**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname:

**Adrian Peres**

<b>Reference: 1.3</b>
<b>European Initiative: EUHealth Programme</b>
<p>EU4Health is the EU's largest health programme in monetary terms, with a budget of €5.3 billion in current prices. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. EU4Health provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe. The EU4Health programme is a key pillar to the Commission's work to strengthen the European Health Union and contribute to the EU's health priorities. The actions funded under the EU4Health programme pursue 4 goals and 10 specific objectives. EU4Health will also be investing in urgent health priorities: response to COVID-19 pandemic and resilience for cross-border health threats; Europe's Beating Cancer Plan; The Pharmaceutical Strategy for Europe. And other areas: the digitalisation of health systems, antimicrobial resistance, improved vaccination rates.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>María José González de Suso</b>
<b>Organisation</b>
Instituto de Salud Carlos III (ISCIII)
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>PhD in Medicine and Surgery. Specialist in Clinical Pharmacology (MIR) and Diploma in Medicine in the Pharmaceutical Industry (UCM). Senior Management Programme in Health Institutions (IESE), Advanced Course in Patents and Technology Transfer (Pons-URJC Foundation) and Master's Degree in R&amp;D&amp;I Management in Health Sciences (ISCIII-UAH-UNED).</p> <p>She has developed his professional career in several areas: in the health care field (NHS Clinical Hospitals in Granada and Madrid), in the National Government (ISCIII and MoHealth), and in Scientific Departments in the private sector of the Pharmaceutical Industry (Bristol-Myers Squibb).</p> <p>From 2007 to the present, she has been working as Director of Programmes in the International Research Programmes and Institutional Relations Department of the Institute of Health Carlos III (ISCIII) - Ministry of Science and Innovation.</p> <p>Since 2014, she acts as the National Focal Point Representative for Spain for the EU Health Programme of DG SANTÉ of the European Commission, having been appointed to hold this position by the MoHealth.</p> <p>Among other European Research Funding Programmes, she also interacts with AAL -Ambient Assisted Living- and JPI MYBL- Joint Programming Initiative More Years Better Life of Horizon Europe, as well as</p>

with IARC- International Agency for Research on Cancer- of the WHO, and other international organisations and institutions in the field of biomedicine.

**Reference: 1.4**

**European Initiative: TRANSCAN-3**

Transnational cancer research is key for addressing, understanding and preventing cancer, a worldwide health concern despite the continuous advancement of research and treatment approaches. The EU-funded TRANSCAN-3 project is bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research. Through cross-national joint calls for proposals and making the most of international and interregional cooperation, TRANSCAN-3 aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational cancer research in Europe and beyond.

**Member of the SWG:**



**Name and Surname**

**Inés Rey Hidalgo**

**Organisation**

FICYT


**Brief CV (the entire profile is expected to take up one page)**

I will contribute to the SWG as partner of the ERANET TRANSCAN-3, which is a s bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research.

I am the manager of the Office of European Projects of FICYT. I have carried out the administrative and financial coordination of three European projects in the field of health and participated as partner in other 11 European projects.

Regarding ERANETs and Partnerships, I take part in the FICYT's team as partner of TRANSCAN-2, TRANSCAN-3, ERA4Health, CETP and FutureFoodS.

I have been working in FICYT managing the regional funding calls launched in the framework of the ERANETs and Partnerships international calls.

<b>Reference: 1.5</b>
<b>European Initiative: ERA PerMed</b>
ERA PerMed is an ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission. The main objective of ERA PerMed is to align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine, and enhance the European collaboration with non-EU countries. National funding organisations will launch Joint Transnational Calls for collaborative research projects in Personalised Medicine.
Member of the SWG:

Name and Surname
<b>María Cristina Nieto García</b>
Organisation
Instituto de Salud Carlos III (ISCIII)
Brief CV (the entire profile is expected to take up one page)
<p>Dr. María Cristina Nieto García is currently Head of the International Research Programmes Unit in the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIIRI) in the National Institute of Health Carlos III (ISCIII). She is actively involved in the coordination, management and follow-up of different programmes related to European and International transnational collaborative research at SGPIIRI. She is the coordinator of ERA4Health Partnership and the coordinator of ERA-Net Co-fund ERA-PerMed. She is also the Spanish representative of the CSA ICPeMed Secretariat and member of the preparatory group of the future Partnership of Personalised Medicine (EP PerMed).</p> <p>Previously, she obtained her PhD in Pharmacy in the Cancer Research Centre of the University of Salamanca in 2011, followed by a multi-year stint as Pharmaceutical Inspector for the Spanish Government. Afterwards, she worked for the Spanish Ministry of Science in Knowledge Transfer and Science Management activities.</p>

**Reference: 1.6**
**European Initiative: EJP RD**

The European Joint Programme on Rare Diseases (EJP RD) is a programme aiming to create an effective rare diseases research ecosystem for progress, innovation and for the benefit of everyone with a rare disease. They support rare diseases stakeholders by funding research, bringing together data resources & tools, providing dedicated training courses, and translating high quality research into effective treatments. EJP RD brings over 130 institutions (including all 24 ERNs) from 35 countries: 26 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Croatia, Ireland, Italy, Netherlands, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Spain, Sweden, Slovakia, Slovenia); 7 associated (Armenia, Georgia, Israel, Norway, Serbia, Switzerland, Türkiye); Uk & Canada.

Member of the SWG:



Name and Surname

**Daria Julkowska**


Organisation

INSERM

Brief CV (the entire profile is expected to take up one page)

Daria Julkowska has a PhD in molecular biology and pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine. She is the Scientific Coordinator of the European Joint Programme on Rare Diseases that brings together over 130 institutions representing different type of stakeholders (researchers, funders, clinicians & patients) from 35 countries from Europe and beyond, and is also responsible for the coordination of the IRDiRC Scientific Secretariat. She is involved in the rare diseases field since 2010. She developed and put into action a set of collaborations facilitating research, including the partnerships with European Research Infrastructures and Patients' Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes and serves as the chair of the Expert Group on support for the strategic coordinating process for European partnerships of the European Commission. In 2020 she received EURORDIS Black Pearls Award for the European Rare Diseases Leadership.

**Reference: 1.7**

<b>European Initiative: JPIAMR</b>
The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, is an international collaborative organization and platform, engaging 29 nations and the European Commission to curb antimicrobial resistance (AMR) with a One Health approach. The JPIAMR coordinates national research funding and supports collaborative action for filling knowledge gaps on AMR with a One Health perspective. Their shared Strategic Research and Innovation Agenda outlines the key areas to be addressed and provides guidance for countries to align their AMR research agendas nationally and internationally.
Member of the SWG:

Name and Surname
<b>Laura Marin</b>
Organisation
Swedish Research Council
Brief CV (the entire profile is expected to take up one page)
Laura Marin coordinates the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) initiative and heads its Executive office Secretariat hosted by the Swedish Research Council. JPIAMR, is an international collaborative platform that coordinates national research funding and supports collaborative research action for filling knowledge gaps on antimicrobial resistance with a One Health perspective. She also leads the preparations of the future European co-funded One Health AMR Partnership. Previously she was responsible for Science Policy and Member Relations at the European Science Foundation in Strasbourg. Earlier on she was team leader of the European Science Open Forum in 2008 and Director of Operations at the Catalan Foundation for Research and Innovation. She has several years of experience in Brussels and Germany managing research and innovation projects and facilitating numerous fora on science policy. She holds a M.Litt in Management, Economics and International Relations from University of St. Andrews, a M.S.c & B.A. in Political Science and Public Administration from Universitat Autònoma de Barcelona and has followed business executive education at IMD Business School Lausanne.

<b>Reference: 1.8</b>
<b>European Initiative: IHI</b>
The Innovative Health Initiative (IHI) is a public-private partnership (PPP) in health between the European Union and the European life science industries, that runs under Horizon Europe, the European framework programme for research and innovation. Their core goals are to translate health research



and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

Member of the SWG:



Name and Surname

**Magali Poinot**

Organisation

IHI JU

Brief CV (the entire profile is expected to take up one page)

Team Leader the Governance Cell of the IHI JU, Magali Poinot oversees the activities relating to the IHI JU Governing Board, Science and Innovation Panel and States' Representatives Group. An important role of coordinating the Task Force on Synergies with other programmes and initiatives, and the preparation of the annual work programmes are also key parts of the function.

During the setting-up of and transition towards IHI JU, Magali acted as the IMI JU focal point for shaping with the European Commission services and the industry partners the new cross-sectorial public-private partnership in Health under Horizon Europe.

Lawyer by training, Magali Poinot is specialised in European Community-funded Research & Development and Innovation programmes (including coordination of national research programs and setting up of major European initiatives) and in Intellectual Property management in transnational collaborative research projects.

Before joining the European Commission (Directorate General Research & Innovation) during several years, Magali worked for French high engineers' schools Ecoles des Mines, a range of intergovernmental initiatives in the field of Science and Technology (such as COST and EUREKA) and coordinated the European IPR-Helpdesk (assistance and support on Intellectual Property to applicants and participants of EU-funded projects). She is also a Board member of the Global Healthcare Innovation Alliance Accelerator (GHIAA).


**Reference: 1.9**

**European Initiative: EP PerMed**

ICPerMed promotes the establishment of a European Partnership for Personalised Medicine, EP PerMed, together with the closely connected ERA-Net ERA PerMed.

Deadlines: SRIA finalization (02/2023) / EP PerMed proposal (04/2023) / EP PerMed lifetime (Q4/2023-2030).

Member of the SWG:


<b>Name and Surname</b>
<b>Wolfgang Ballensiefen</b>
<b>Organisation</b>
DLR PT
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p><u>Profile</u></p> <ul style="list-style-type: none"> <li>•Project management for health research funding measures on the European level and nationally on behalf of the German Federal Ministry of Education and Research</li> <li>•Policy advise, e.g. in the areas of personalised medicine and cardiovascular research</li> <li>•Author or co-author of several strategic European publications in the area of health research, e.g. the Vision Paper of the International Consortium for Personalised Medicine, the Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD) or the Strategic Research and Innovation Agenda for personalised Medicine (SRIA PerMed),</li> <li>•Expertise in a wide range of public relation activities, e.g. press workshops and disease-specific publications</li> <li>•Publications (peer review)</li> </ul> <p><u>References</u></p> <p>Since 2022; Coordinator of the EP PerMed proposal and the related SRIA 2023. Since 2021; Coordinator of the Coordination and Support Action (CSA) ICPeMed Secretariat. 2019-2022; Coordinating partner of the CSA for Strengthening Training of Academia in Regulatory Science (CSA STARS). 2019-2022; Partner of the CSA to develop Health Economic and Payment Models for Personalised Medicine (CSA HEcoPerMed). From 2016; Representative of the German Federal Ministry for Education and Research and until 2020 vice-chair of the International Consortium for Personalised Medicine (ICPerMed). 2015-2022; Coordinator of the ERA-Net Cofund action dedicated to cardiovascular diseases and co-funded by the European Commission, ERA-CVD. 2013 – 2015 Coordinator of the CSA for Personalised Medicine (CSA PerMed)</p> <p><u>Work Experience</u></p> <p>- Since 2000: German Aerospace Center, Project Management Agency, Health (ID-GE), Innovation for disease related research, Personalised Medicine (GE-IKB)</p> <p>- 1997 – 2000: Researcher (Postdoc) at the Medical Research Council (MRC) Laboratory for Molecular Cell Biology (LMBC) at the University College in London (UCL)</p>

<b>Reference: 1.10</b>
<b>European Initiative: BE READY</b>
The main goal of BE READY is to build a consolidated European Research and Innovation Area that provides the foundation of the candidate European partnership for pandemic preparedness so to improve the EU's preparedness to predict and respond to emerging health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. The Partnership is expected to

build on existing pandemic preparedness networks, and work in synergy with the Health Emergency Response Authority (HERA), in close collaboration with ECDC, EMA and other relevant international and European actors. BE READY is composed by 24 organisations from 15 countries with complementary expertise and policy area ranging from Public Health Organisations, Ministries (of Science, University, Health, Innovation or Environment) and Research Performing Organisations that ensures a cross-cutting, interdisciplinary Global Health and One Health approach.

Member of the SWG:



Name and Surname

**Hervé Raoul**

Organisation

ANRS Emerging Infectious Diseases

Brief CV (the entire profile is expected to take up one page)

Education

PhD in Biology of Blood Cells (1995, University of Paris 7, France)

Accreditation to supervise research (HDR) in Toxicology (2000, University of Paris XI, France).

Work History

Hervé Raoul is Director of Research at Inserm and Deputy Director of the ANRS-MIE (ANRS – Emerging Infectious Diseases) since July 2021. He has been Director of the Inserm Jean Mérieux BSL4 laboratory located in Lyon from October 2005 to September 2022. He is and has been actively involved in various international collaborations and in European-funded programs and has created in July 2017 the pan-European infrastructure dedicated to RG4 pathogens study. He is member of various national and international scientific advisory boards.

**Reference: 1.11**

**European Initiative: ERA Net NEURON**

This initiative was launched under the 6th Framework Programme of the European Commission as an ERA-NET – a platform to coordinate collaborative action between funding bodies and foster a European Research Area (ERA). The participating partner organisations are major stakeholders and provide considerable funding for disease-related neuroscience in their countries. They agree that excellent research is a prerequisite to overcome the societal burden of brain diseases and that such research

requires promotion and investment in an internationally concerted action. NEURON partners support research that is directed at a better understanding of brain and nervous system diseases and their progression in order to pave the way for new or improved routes for diagnosis and therapy.

Member of the SWG:



Name and Surname

**Dr. Hella Lichtenberg**

Organisation

DLR e.V. Project Management Agency | Health Research

Brief CV (the entire profile is expected to take up one page)


Hella Lichtenberg, PhD, ERA-NET NEURON is a trained geneticist with a habilitation in microbiology. Since 2007 she is responsible for NEURON's, since 2015 was also for ERA-CVD's (Cardiovascular Diseases) coordination office, and was since 2018 actively engaged in the EBRA project (Brain Research). The involvement in the international measures necessitates all areas of conceptualizing and executing research funding programmes including overarching topics like PPI, quality assurance in biomedical research, and ethical issues.

**Reference: 1.12**


**European Initiative: JPND Research**

JPND aims to confront the growing challenge posed by neurodegenerative diseases in our ageing population by bringing together researchers, existing research evidence and national funding bodies to investigate the key research questions and barriers to progress in this area. The neurodegenerative diseases that JPND focuses on are: Alzheimer's disease (AD) and other dementias; Parkinson's disease (PD) and PD-related disorders; Prion disease; Motor neurone diseases (MND); Huntington's disease (HD); Spinocerebellar ataxia (SCA); Spinal muscular atrophy (SMA).


Member of the SWG:


<b>Name and Surname:</b>
<b>Philippe Amouyel</b>
<b>Organisation</b>
Lille university / Inserm / Institut Pasteur de Lille
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Professor of Epidemiology and Public Health at the medical School and University Hospital of Lille, France (PU-PH)</p> <p>Philippe Amouyel, MD, PhD, chairs the EU Joint Programme on Neurodegenerative Diseases research (JPND), a 30-country led initiative aimed at tackling the challenge of neurodegenerative diseases, the largest global research collaboration on neurodegenerative diseases. He is Professor of Epidemiology and Public Health at the University Hospital of Lille in France. He heads a large academic research unit working on public health and molecular epidemiology of aging diseases. He develops epidemiological studies to attempt to decode susceptibility to ageing diseases, using molecular techniques such as high-throughput genomics, transcriptomics, proteomics, and bioinformatics. His research is devoted to the study of determinants, mainly genetic, of neurodegenerative diseases associated with cognitive decline and Alzheimer's disease in particular. He participated in the discovery of more than 90% of the genetic susceptibility published in Alzheimer's disease. He published 749 original articles and reviews in international journals (h-index = 122; average citations per item 115; highly cited researcher 2018, Web of Science, Clarivate). Since 2008, he has been the general director of Fondation Alzheimer (France), a private non-profit foundation dedicated to supporting innovative and cutting-edge research for Alzheimer's disease and related disorders.</p> <p><b>Main publications</b></p> <p>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Lambert JC et al., Nat Genet 2013;45:1452-1458</p> <p>Defeating Alzheimer's disease and other dementias: a priority for European science and society. Winblad B, Amouyel P, Andrieu S et al., Lancet Neurol. 2016;15:455-532</p> <p>Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic. Meyers EA, Amouyel P et al., Alzheimers Dement 2022;18:1067-1070</p> <p>New insights into the genetic etiology of Alzheimer's disease and related dementias. Bellenguez C et al., Nat Genet. 2022;54:412-436</p>

--

<b>Reference: 1.13</b>
<b>European Initiative: OH AMR Partnership</b>
The CSA DESIGN OH AMR, in collaboration with JPIAMR and other stakeholders is leading the development of the One Health AMR Partnership. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aimed at reducing the threat of antimicrobial resistance (AMR). The SRIA and proposal submission to the EC is foreseen in 2024. The first call and launch of other activities of this joint research programme between the European Commission and Member States are planned to take place in 2025.
Member of the SWG:

Name and Surname
<b>Laura Marin</b>
Organisation
Swedish Research Council
Brief CV (the entire profile is expected to take up one page)
<p>Laura Marin coordinates the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) initiative and heads its Executive office Secretariat hosted by the Swedish Research Council. JPIAMR, is an international collaborative platform that coordinates national research funding and supports collaborative research action for filling knowledge gaps on antimicrobial resistance with a One Health perspective. She also leads the preparations of the future European co-funded One Health AMR Partnership. Previously she was responsible for Science Policy and Member Relations at the European Science Foundation in Strasbourg. Earlier on she was team leader of the European Science Open Forum in 2008 and Director of Operations at the Catalan Foundation for Research and Innovation. She has several years of experience in Brussels and Germany managing research and innovation projects and facilitating numerous fora on science policy. She holds a M.Litt in Management, Economics and International Relations from University of St. Andrews, a M.S.c &amp; B.A. in Political Science and Public Administration from Universitat Autònoma de Barcelona and has followed business executive education at IMD Business School Lausanne.</p>

<b>Reference: 1.14</b>
------------------------

<b>European Initiative: ICP PerMed</b>
ICPerMed provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation, in which over 30 European and international partners representing ministries, funding agencies and the European Commission (EC) work together on coordinating and fostering research to develop and evaluate personalised medicine approaches.
Member of the SWG:

Name and Surname
<b>Wolfgang Ballensiefen</b>
Organisation
DLR PT
Brief CV (the entire profile is expected to take up one page)
<p><u>Profile</u></p> <ul style="list-style-type: none"> <li>•Project management for health research funding measures on the European level and nationally on behalf of the German Federal Ministry of Education and Research</li> <li>•Policy advise, e.g. in the areas of personalised medicine and cardiovascular research</li> <li>•Author or co-author of several strategic European publications in the area of health research, e.g. the Vision Paper of the International Consortium for Personalised Medicine, the Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD) or the Strategic Research and Innovation Agenda for personalised Medicine (SRIA PerMed),</li> <li>•Expertise in a wide range of public relation activities, e.g. press workshops and disease-specific publications</li> <li>•Publications (peer review)</li> </ul> <p><u>References</u></p> <p>Since 2022; Coordinator of the EP PerMed proposal and the related SRIA 2023. Since 2021; Coordinator of the Coordination and Support Action (CSA) ICPPerMed Secretariat. 2019-2022; Coordinating partner of the CSA for Strengthening Training of Academia in Regulatory Science (CSA STARS). 2019-2022; Partner of the CSA to develop Health Economic and Payment Models for Personalised Medicine (CSA HEcoPerMed). From 2016; Representative of the German Federal Ministry for Education and Research and until 2020 vice-chair of the International Consortium for Personalised Medicine (ICPerMed). 2015-2022; Coordinator of the ERA-Net Cofund action dedicated to cardiovascular diseases and co-funded by the European Commission, ERA-CVD. 2013 – 2015 Coordinator of the CSA for Personalised Medicine (CSA PerMed)</p> <p><u>Work Experience</u></p> <ul style="list-style-type: none"> <li>- Since 2000: German Aerospace Center, Project Management Agency, Health (ID-GE), Innovation for disease related research, Personalised Medicine (GE-IKB)</li> <li>- 1997 – 2000: Researcher (Postdoc) at the Medical Research Council (MRC) Laboratory for Molecular Cell Biology (LMBC) at the University College in London (UCL)</li> </ul>

<b>Reference: 1.15</b>
<b>European Initiative: IRDiRC</b>

IRDiRC is a global collaborative initiative launched in 2011 by the European Commission and the US National Institutes of Health to tackle rare diseases through research and accomplish the vision to enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention.

Today, the Consortium gathers 60 member organizations from all continents. Members' representatives are organized into the Constituent Committees of Funders, Companies and Umbrella Patient Advocacy Groups, and collaborate with international experts nominated into the Diagnostics, Therapies and Interdisciplinary Scientific Committees.

Through its broad representation, IRDiRC works towards the mission of advancing diagnostics and treatments, and of understanding the impact of these, for all people living with a rare disease (specific Task Force on Clinical Research Networks for Rare Diseases).

Member of the SWG:



Name and Surname

**Daria Julkowska**

Organisation

INSERM

Brief CV (the entire profile is expected to take up one page)

Daria Julkowska has a PhD in molecular biology and pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine. She is the Scientific Coordinator of the European Joint Programme on Rare Diseases that brings together over 130 institutions representing different type of stakeholders (researchers, funders, clinicians & patients) from 35 countries from Europe and beyond, and is also responsible for the coordination of the IRDiRC Scientific Secretariat. She is involved in the rare diseases field since 2010. She developed and put into action a set of collaborations facilitating research, including the partnerships with European Research Infrastructures and Patients' Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes and serves as the chair of the Expert Group on support for the strategic coordinating process for European partnerships of the European Commission. In 2020 she received EURORDIS Black Pearls Award for the European Rare Diseases Leadership.

**Reference: 1.16**

**European Initiative: EU-Africa PerMed Project**

The EU-Africa PerMed project has the overall aim of integrating African countries into ICPeMed activities, thus contributing to a successful implementation of Personalised Medicine (PM) in the global



context. It will foster joint PM projects and programmes between Europe and Africa, as well as strengthening bilateral EU-AU science, technology and innovation (STI) relations in the area of health. The project started on the 1st. of February 2021 and will last 4 years. It is implemented by a consortium of 13 partners, 6 from Europe and 7 from Africa and is organized around 7 main Work Packages.

Member of the SWG:



Name and Surname

**Erika Sela**


Organisation


INNOVATEC


Brief CV (the entire profile is expected to take up one page)


Erika Sela is Senior Consultant and co-founder of Innovatec, a Spanish consultancy firm with a broad and long-term expertise in R&I activities. She has a bachelor's degree in Biology. She has over 30 years' experience in R&D management activities in different positions and organizations. In the last years, her main activity has been dedicated to European projects.

She is now the coordinator of the H2020 project **EU-Africa PerMed: Building Links Between Europe and Africa in Personalised Medicine**. The project seeks to facilitate and strengthen research and innovation collaboration between Europe and Africa in Personalised Medicine (PM), fostering joint projects and programmes as well as facilitating the participation of African organizations in the international Consortium for Personalized Medicine (ICPerMed).

<b>Reference: 1.17</b>
<b>European Initiative: CSA IC2PerMed</b>
Integrating China in the International Consortium for Personalised Medicine (IC2PerMed) project aims to support EU-China collaboration over the developments of Personalised Medicine research, innovations and policies through the ICPeMed initiative, providing people with access to personalised, smart and inclusive healthcare solutions in the near future.
Member of the SWG:

Name and Surname
<b>Stefania Boccia</b>
Organisation
Section of Hygiene, Institute of Public Health, Università Cattolica del Sacro Cuore (UCSC), Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS, Rome, Italy
Brief CV (the entire profile is expected to take up one page)
<p>Stefania Boccia is Full professor of Hygiene, Preventive Medicine and Public Health at UCSC in Rome, and Research Director for IRCCS FPG.</p> <p>She is Deputy Research Director of the IRCCS FPG and Affiliate of the Meta-Research Innovation Center at Stanford, Stanford, UK.</p> <p>She is the President of the European Public Health Epidemiology Section of the European Public Health Association (EUPHA), Associate Editor of European Journal of Epidemiology and European Journal of Public Health, Member of the Advisory Board of the Lancet Regional Health-Europe.</p> <p>She currently coordinates the EU funded projects “European network staff eXchange for integrAting precision health in the health Care sysTems” (ExACT) and “A PeRsOnalized Prevention roadmap for the future HEalThcare” (PROPHET).</p> <p>She coordinates the “Interaction of genomic and dietary aspects in gastric cancer risk: the global StoP project” project, funded by the Italian Ministry of Health, Bando 2022 Ricerca Finalizzata, the “Innovative approaches for personalised cardiovascular prevention: multicentre randomised controlled study and multidisciplinary evaluation for a National Health Service implementation” project, funded by the Italian Ministry of Health, PNRR: M6/C2_CALL 2022, and the “Generation Gemelli: longitudinal study for the evaluation of maternal exposome on the newborn and child health” project, funded by UCSC (linea D3, University research projects of interest).</p> <p>She has an H index of 52 and 9702 citations at march 2023</p>

<b>Reference: 1.18</b>
<b>European Initiative: THCS Partnership</b>
<p>The general objective of the European Partnership “Transforming Health and Care Systems” is to contribute to the transition towards more sustainable, efficient, resilient, inclusive, innovative and high-quality people-centred health and care systems equally accessible to all people. For this purpose, THCS aims not only to create new knowledge and scientific evidence but to co-design new solutions and support their transfer and scale-up across countries and regions while also fostering capacity building. The approach for a successful and smooth implementation of THCS will focus on three main work streams: 1) Filling the knowledge gaps with research actions aiming at providing the necessary evidence, 2) Implementation and transfer aiming at supporting actions focusing on the testing of existing solutions and adaptability in different national and regional contexts, and 3) Boosting health and care systems through dedicated activities (capacity building and trainings, study visits, technical assistance, twinning, networking) involving different health and care stakeholders.</p>

<b>Name and Surname</b>
<b>Chiara Ciccarelli</b>
<b>Organisation</b>
Italian Ministry of Health
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Chiara Ciccarelli is an International Relations Officer at the Italian Ministry of Health, Directorate General for Research and Innovation in Healthcare.</p> <p>She has an MD in Translation for special purposes focused on legal and medical sectors and is currently achieving a Master’s in Management and Government of Public Administrations as well as a second MD in Political Sciences and International Relations.</p> <p>She is in charge of supervising the International Biomedical Research activities the Italian Ministry of Health is involved in through its IRCCS (Scientific Institute for Research, Hospitalization and Healthcare). She has been involved in several initiatives clustered in the FP “Horizon 2020” and is currently involved in further actions supported by the FP “Horizon Europe”, among which, is the European Partnership “Transforming Health and Care Systems”, of which the Italian Ministry of Health is the coordinator.</p> <p>Moreover, she also supports the Italian Ministry of Foreign Affairs and International Cooperation in the scientific activities jointly carried out under the Scientific and Technological Bilateral Cooperation Agreements.</p>

<b>Reference: 1.18</b>
<b>European Initiative: THCS Partnership</b>
<p>The general objective of the European Partnership “Transforming Health and Care Systems” is to contribute to the transition towards more sustainable, efficient, resilient, inclusive, innovative and high-quality people-centred health and care systems equally accessible to all people. For this purpose, THCS aims not only to create new knowledge and scientific evidence but to co-design new solutions and support their transfer and scale-up across countries and regions while also fostering capacity building. The approach for a successful and smooth implementation of THCS will focus on three main work streams: 1) Filling the knowledge gaps with research actions aiming at providing the necessary evidence, 2) Implementation and transfer aiming at supporting actions focusing on the testing of existing solutions and adaptability in different national and regional contexts, and 3) Boosting health and care systems through dedicated activities (capacity building and trainings, study visits, technical assistance, twinning, networking) involving different health and care stakeholders.</p>

<b>Name and Surname</b>
<b>Francesca Turco</b>
<b>Organisation</b>
Italian Ministry of Health
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Francesca Turco is a Health Officer at the Italian Ministry of Health, Directorate General for Research and Innovation in Healthcare.</p> <p>She is a biologist, specialising in Nutrition Science. She worked at various facilities in the National Health System, such as the hospital oncology and preventive dietetics clinics departments.</p> <p>She is involved in both National Finalized and Current Research. In the area of Finalized Research, she is in charge of monitoring and scientifically evaluating the interim and final reports concerning the funded projects submitted by the IRCCS, controlling also the validity and consistency of the related documents. In the area of Current Research, she is in charge of evaluating the compliance of the produced publications with the evaluation criteria established within the IRCCS triennial planning.</p> <p>She has been involved in several initiatives clustered in the FP “Horizon 2020” and is currently involved in further actions supported by the FP “Horizon Europe”, among which, is the European Partnership “Transforming Health and Care Systems”, of which the Italian Ministry of Health is the coordinator.</p>

<b>Reference: 1.19</b>
<b>European Initiative: FLASH - Flexible Approaches to Support Health through Financing</b>
FLASH, a Horizon Europe project (Topic: “Better Financing Models for Health Systems”; 2023-2026), undertakes a comprehensive analysis of health care financing mechanisms in Europe and, by employing a wide range of methodological approaches, it provides evidence on the ability of existing financing mechanisms and contracts to address such challenges and study new solutions to achieve more effective, efficient and equitable health care systems.

Name and Surname
<b>Paolo Pertile</b>
Organisation
University of Verona (Italy)
Brief CV (the entire profile is expected to take up one page)
<p>Current Position :</p> <p>Professor of Public Economics, Department of Economics, University of Verona.          Leader of the research unit of the University of Verona, coordinator of the project FLASH (Flexible Approaches to support Health through Financing).</p> <p>Education:</p> <ul style="list-style-type: none"> <li>• Ph.D; “Graduate School in the Economics and Finance of Public Administration”, a joint programme of Catholic University, Bicocca University and University of Milan (Milan, Italy)</li> <li>• MSc. in “Public Economics”, University of York (UK)</li> <li>• B.A. (4-year degree) in “Economics and Business”. University of Verona (Italy).</li> </ul> <p>Research interests:</p> <p>Economic implications of health care regulation (payment rules, competition), pharmaceutical regulation and innovation, economic evaluation of health care interventions (methodology and applications), economic implications of public sector intervention over the life-cycle.</p> <p>Selected publications:</p> <ul style="list-style-type: none"> <li>• “R&amp;D and market size: who benefits from orphan drug legislation?”; Journal of Health Economics; 2021; vol 80 (with S. Gamba and L. Magazzini).</li> <li>• “The impact of Managed Entry Agreements on pharmaceutical prices”; Health Economics; 2020; vol 29 S1, pp. 47-62 (with S. Gamba e S. Vogler).</li> <li>• “Which valued-based price when patients are heterogeneous?”; Health Economics; 2020; vol 29, pp. 923-935. (with R. Levaggi).</li> <li>• “A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response”; Journal of the Royal Statistical Society Series B; 2017; vol 79 (5), pp. 1439-1462 (with S. Chick and M. Forster).</li> </ul>

- “Static and dynamic efficiency of irreversible health care investments under alternative payment rules”; *Journal of Health Economics*, 2012, vol. 31, n. 1, pp. 169-179 (with R. Levaggi and M. Moretto).

**Reference: 1.20**
**European Initiative: PRUDENT Prioritization, incentives and Resource use for sUstainable DENTistry**

PRUDENT (Prioritization, incentives and Resource use for sUstainable DENTistry) project aims to develop and implement an innovative and context-adaptive framework for optimized financing of oral care. PRUDENT brings together top investigators from prestigious universities, public authorities and policymakers, civil society and patient organizations, health insurers, and health professionals, to achieve a step change in collective problem solving. Given the comprehensiveness of the topic, PRUDENT uses a targeted approach that is entirely focused on four major root-causes underlying the current limitations of oral care financing.

**Picture**

**Name and Surname**

Stefan Listl

**Organisation**

Radboud University, Heidelberg University

**European Initiative**

PRUDENT, DELIVER

**Brief CV (the entire profile is expected to take up one page)**

Stefan Listl is a dentist and economist. He is full professor at Radboud University (Netherlands), extraordinary professor at Heidelberg University (Germany), and adjunct professor at the University of Pennsylvania (USA).

Stefan currently serves as coordinating PI for the Horizon Europe projects PRUDENT (Prioritization, Incentives and Resource Use for Sustainable Dentistry) and DELIVER (Deliberative Improvement of Oral Care Quality). He also coordinates the German Innovation Fund projects DigIn2Perio (Digitally Integrated Type-2 Diabetes and Periodontitis Care) and Paro-ComPas which leverage digital tools and patient

empowerment to enhance medical-dental integration. He previously served as a PI for the EU Horizon 2020 project ADVOCATE (Added Value for Oral Care) where he coordinated the big data analytics and health economics workstreams. In a research project funded by NIH (USA), he served as Co-PI to analyse cross-country variations in older adults' dental coverage and out-of-pocket payments. His total grant acquisition exceeds €23 million.

Stefan is a member of the Lancet Commission on Global Oral Health and chair of the WHO Working Group for Cost-Efficient Oral Health Interventions ("Best Buys" for Oral Health). He previously served as a consultant for Harvard University's Malaysia Health Systems Reform project, and contributed to the WHO Global Oral Health Status Report, the first ever NIH Report on Oral Health in America, the FDI World Dental Federation Vision 2030 report, and the oral health standard set of the International Consortium for Health Outcomes Measurement (ICHOM). He spoke at oral health events during United Nations High-Level Meetings, at the EU Parliament and in the Dutch House of Representatives.

He is author of more than 120 journal publications, including in Lancet, Nature, Bulletin of the WHO, Journal of Health Economics, Health Economics, American Journal of Epidemiology, American Journal of Public Health, Social Science & Medicine, and Journal of Dental Research. He is editorial board member for the Journal of Dental Research and the Journal of Evidence-based Dental Practice and regularly reviews for journals and funding institutions.

**Reference: 1.21**

**European Initiative: ECHoS - Establishing of Cancer Mission Hubs: Networks and Synergies**

ECHoS is an European project, funded by **Horizon Europe Programme**, that aims to support the implementation of the **Cancer Mission** activities in all Member State and Associated Country (MS/AC) through the establishment and development of **National Cancer Mission Hubs (NCMHs)** operating at national, regional, and local levels.

Picture




Name and Surname

Hugo Soares

Organisation

AICIB - Agência De Investigação Clínica E Inovação Biomédica

<b>European Initiative</b>
ECHoS - Establishing of Cancer Mission Hubs: Networks and Synergies
<b>Brief CV (the entire profile is expected to take up one page)</b>
Hugo Soares, PhD, works as science manager at AICIB. He is an expert in stakeholders and project management in the Cancer area. Currently, Hugo acts as co-coordinator of the European project ECHoS and, as co-coordinator of the Portuguese National Cancer Hub (NCH-PT). The ECHoS project aims at Establishing Cancer Mission Hubs and to create networks of support to EU Mission on Cancer through synergies and community engagement. The Portuguese National Cancer Hub (NCH-PT), a structure dedicated to connecting people and organizations to foster the translation of scientific evidence into policies. The NCH-PT is oriented towards the implementation of EU Mission on Cancer and EBCP initiatives in the full spectrum of cancer - from fundamental research to clinical research and clinical practice. The NCH-PT catalyses the development of multi-stakeholders' projects and connections to the community in Health, Research and beyond.

<b>Reference: 2.1</b>
<b>European Initiative: Water4All</b>
The Water4All Partnership - Water Security for the Planet - is co-funded by the European Union within the frame of the Horizon Europe programme (a key funding programme for research and innovation). The Partnership duration is for seven years from 2022. The objectives are to tackle water challenges as means to face climate change, help to achieve the United Nations' Sustainable Development Goals and boost the EU's competitiveness and growth. There are 7 key themes: IV) Water and health. Anti-Microbial Resistance (AMR) is considered an imminent global public health threat.
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Juliette Arabi</b>
<b>Organisation</b>
French National Research Agency (ANR)
<b>Brief CV (the entire profile is expected to take up one page)</b>
Juliette Arabi holds a Ph.D. in molecular biology and she has 10+ years' experience in project management. She is currently international project officer in the "Environment, Ecosystems, and Biological Resources" department at the French National Research Agency (ANR) in Paris. She is trained to work in multidisciplinary and multicultural environments, and to manage multilateral activities. For the past eight years, she has been working in the coordination of the Joint Programming Initiative on "Water challenges for a changing world" - Water JPI. She was also involved in various European



projects, including the management of the IC4Water CSA for the development of international cooperation in the water area, and the implementation of additional activities in the scope of several ERA-NETs Cofund, WaterWorks2014, WaterWorks2015, WaterWorks2017 and BiodivRestore. Since June 2022, she works in the coordination team of the Water4All Partnership, a multiannual and multidisciplinary initiative co-financed by the European Commission within the Horizon Europe framework programme. Water4All aims to structure research and innovation in the water sector in Europe and internationally, gathering over 90 partners from 33 countries. Water4All objectives are to tackle water challenges as means to face climate change, help to achieve the UN SDGs and boost the EU competitiveness and growth.

Juliette’s interest for water issues and their interconnection with health started in 2011 when she worked in southern America for the implementation of a ceramic water filter factory in Ecuador. As representative of ANR, funding partner organisation, she took part in the development and follow-up of the Water JPI Knowledge Hub on contaminants of emerging concern.

**Reference: 2.2**

**European Initiative: FutureFoodS**

Food not only supports human life and good health, but also currently has a large social, cultural, environmental and economic dimension. However, the food systems are facing global challenges such as population overgrowth, urbanisation, migration, climate change and resources scarcity. To tackle the effects of these complex social and ecological challenges, we need to innovate in our food systems, to adapt and to prepare them for the future. In addition, Food systems should deliver food security and ensure nutrition security. Providing food and nutrition security (FNS) in the context of a changing world requires urgent political actions, a long-term approaching and civil society commitment. The European R&I (research and innovation) policy plays a crucial role in future proofing food systems, and contributes to achieving the Sustainable Development Goals priority for 2030.

In this sense, the main mission of SCAR FOOD SYSTEMS STRATEGIC WORKING GROUP (SCAR FS SWG) is to provide strategic advice and orientation, and to support the EU R&I policy framework FOOD2030 and its four priorities: NUTRITION for sustainable and healthy diets; CLIMATE smart and environmentally sustainable food systems; CIRCULARITY and resource efficient food systems; INNOVATION and empowerment of communities.

**Member of the SWG:**




**Name and Surname:**

<b>Gilles Feron</b>
Organisation
French National Research Agency (ANR)
Brief CV (the entire profile is expected to take up one page)
<p>Gilles Feron is a research director at INRAE (National Research Institute for Agriculture, Food and the Environment), at the Centre for Taste and Feeding Behaviour (CSGA, Dijon, France), where he has been Deputy Director since 2021. He received a PhD in plant biology &amp; technology from the Institut National Polytechnique (Toulouse, France). His main research topic has always been the investigation of food flavors metabolism and in particular the identification and regulation of biochemical and enzymatic mechanisms involved in their formation in complex biological systems (from plants to humans). He is currently working on the importance of the oral sphere and saliva in the formation, release and perception of aroma and taste compounds during food consumption. He is conducting his research on specific (children, seniors, obese) and pathological (cancer) populations. He has published more than 140 articles, book chapters and patents. He presented his research at over 120 national and international scientific meetings. He was a member of the scientific committee of the food oral processing conference series on which he was the chairman of the second edition in 2012. He has supervised numerous master students and young researchers. He has been involved in National and European research contracts as the scientific manager as well as the coordinator and in numerous industrial projects.</p> <p>Since November 2022, Gilles Feron has been involved as a coordinator in building FutureFoodS, the European Sustainable Food Systems Partnership for People, Planet and Climate. In September 2023, he will be hired as a scientific officer at the French National Research Agency (ANR) to ensure the coordination of FutureFoodS.</p>

<b>Reference: 2.3</b>
<b>European Initiative: SBEP</b>
<p>The Sustainable Blue Economy Partnership is a Horizon Europe co-funded partnership. It constitutes a network of 60 Partner institutions from 25 countries and the European Commission that enables an unprecedented effort to pool research and innovation investments and align national programmes at pan-European scale, taking into consideration the sea-basin (Mediterranean, Black Sea, Baltic and North Sea) and Atlantic Ocean dimension. Intervention areas: 4) Healthy 'Blue Food' under a 'One Health' approach; 5) Enabling the green transitions of 'Blue Food' production</p>
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname:
<b>Maurice Heral</b>

<b>Reference: 2.4</b>
<b>European Initiative: FACCE-JPI</b>
In the last years, climate change and food and nutrition security have become high-level priorities in the policy agenda both at national and global levels. The Joint Programming Initiative on Agriculture, Food Security and Climate Change (FACCE-JPI) was launched in 2010, and currently brings together 24 member countries <sup>1</sup> . Its aim is to build the European Research Area (ERA) tackling the challenges at the intersection of agriculture, food security and climate change that cannot be addressed solely at the national level.
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname:
<b>Heather McKhann</b>

<b>Reference: 2.5</b>
<b>European Initiative: EU Partnership Animal Health and Welfare</b>
The European Partnership Animal Health & Welfare (EUP AH&W) intends to be a Research and Innovation Partnership set up in the context of Horizon Europe. Its general goals are to progress Europe towards healthy and sustainable livestock production systems (for both terrestrial and aquatic animals), including the reduction of anti-microbial usage, and to greatly improve production animal welfare, in line with the European Green Deal and farm-to-fork strategy. Furthermore, the EUP AH&W will enhance public health and well-being by facilitating cross-sector collaboration in a One Health – One Welfare perspective.
Member of the SWG:

Name and Surname
<b>Agnès Roba</b>
Organisation
Fonds de la Recherche Scientifique – FNRS (F.R.S.-FNRS)
Brief CV (the entire profile is expected to take up one page)
-December 2022 - today: Policy Officer at F.R.S.-FNRS – international affairs (Belgium) • Management of European Partnerships in the field of life sciences and

health

-2017-2022: PhD in Biological Sciences at the University of Namur (Belgium)

- Orientation: Molecular and Medical Microbiology
- Topic: "Histidine biosynthesis, cell separation and copper resistance in the pathogenic bacterium *Brucella abortus*"

-2017 (5 months): Research Intern at University of California Davis (USA)

- Orientation: Molecular and Medical Microbiology

-2015-2017: Master's degree in Biochemistry and Molecular Biology at the University of Namur (Belgium)

-2012-2015: Bachelor's degree in Biological Sciences at the University of Namur (Belgium)

**Reference: 2.6**

**European Initiative: NordForsk**

NordForsk is an organisation under the Nordic Council of Ministers that provides funding for and facilitates Nordic cooperation on research and research infrastructure.

Member of the SWG:



Name and Surname


**Kristin Andersen**

Organisation

NordForsk

Brief CV (the entire profile is expected to take up one page)

- February 2023: Special adviser Health and care, NordForsk.org
- September 2019: Special adviser, coordinator and team leader Health and care and welfare systems, The Norwegian Research Council
- June 2015- Senior adviser and NCP for health, delegate in SC1 PC, The Norwegian Research Council
- 2008-2015, Researcher, Institute for Cancer Research, Oslo University Hospital
- 2006-2007, Visiting Postdoc, Lawrence Berkeley Lab, Berkeley, CA, US
- 2005-2006 Postdoc, Institute for Cancer Research, Oslo University Hospital
- 1999-2004 PhD student, Institute for Cancer Research, Oslo University Hospital

<b>Reference: 2.7</b>
<b>European Initiative: PRO-Ethics</b>
<p>PRO-Ethics is working with research and innovation funding organisations across Europe to test new, ethical ways to involve citizens in decision making processes.</p> <p>PRO-Ethics will deliver some very concrete outputs in the form of an ethics framework, together with a set of practical guidelines and actionable criteria for assessing the quality and ethics of participation processes. They have the potential to benefit stakeholders across the EU and beyond.</p>
Picture

Name and Surname
<b>Stefanie Schuerz</b>
Organisation
<b>Centre for Social Innovation - ZSI</b>
European Initiative
<b>PRO-Ethics</b>
Brief CV (the entire profile is expected to take up one page)
<p>Stefanie Schuerz studied sociology and science and technology studies at the University of Vienna. She works as a researcher, project manager and coordinator at the Centre for Social Innovation (ZSI) on research and innovation projects covering topics including research ethics and RRI, Citizen (Social) Science, Open Science, and data governance. Her methodological competencies include broad multi-stakeholder-</p>

engagement processes along the quadruple helix, citizen engagement, and the evaluation and impact assessment of R&I projects. Stefanie has extensive experience in low-threshold participatory action including with vulnerable groups. As coordinator of the RRI project PRO-Ethics, she was involved in the development of the “PRO-Ethics Framework and Guidelines,” which provides a guide for research funding organizations implementing participatory activities. In addition to her work at ZSI, Stefanie provides support to Citizen Science Initiatives in the form of mentoring.

**Reference: 3.1**
**European Initiative: ECRIN**

ECRIN is a European research infrastructure that facilitates researchers to set up and conduct multinational clinical trials in Europe. We do this by linking with our national European Correspondents, the national networks of clinical trial units, and through our services and tools. ECRIN is based in Paris (France), we work with our 12 member countries across Europe, as well as, additional European or international partners. Our network consists of over 120 clinical trial units, our clinical trial portfolio now counts 70 multinational trials with a mean of 6.3 countries per trial, we have participated in more than 40 international infrastructure development projects, and ECRIN is ISO 9001:2015 certified for its core services.

**Member of the SWG:**

**Name and Surname**
**Marta del Álamo**
**Organisation**

ECRIN

**Brief CV (the entire profile is expected to take up one page)**

Marta del Alamo is Project Manager at ECRIN in Paris. She is focused on coordinating ongoing multinational clinical trials in several European countries and providing support to clinical investigators preparing clinical studies/projects for European funding. Marta is also actively involved in ECRIN's capacity building / infrastructure development activities.

Previously Marta worked at SCReN, the Spanish Clinical Research Network, as project manager and was a member of the Ethics Committee at Hospital Ramon y Cajal in Madrid. As a previous research scientist in the field of molecular biology and virology, she has worked at Centro de Biología Molecular Severo Ochoa and Centro Nacional de Biotecnología (Spain) and Scripps Research Institute, Washington University in St Louis and Stanford University (USA).

Marta received a BA in biology (biotechnology) from Universidad Complutense de Madrid, and a PhD in molecular biology from Universidad Autónoma de Madrid. She also did a post-graduate programme in clinical trials management in Madrid.

**Reference: 3.2**

**European Initiative: EATRIS**

EATRIS is the European infrastructure for translational medicine. They bring together resources and services for research communities to translate scientific discoveries into benefits for patients. They are a non-profit organisation that provides access to a vast array of expertise and facilities from 144+ top-tier academic centres across Europe. They focus on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics, and overcome barriers to health innovation.

Their research infrastructure offers a broad range of research services for both academia and industry across various research fields. In addition, we work with public funding agencies, charities and policy makers with tailored actions to help improve the translational research and innovation ecosystem.

The EATRIS community comprises world class facilities providing collaborative services in ATMPs (Advanced Therapeutic Medicinal Products), among other areas.

**Member of the SWG:**



**Name and Surname**

**Anton Ussi**

**Organisation**

EATRIS ERIC

**Brief CV (the entire profile is expected to take up one page)**


Anton Ussi (MSc) is Operations & Finance Director at EATRIS ERIC, the ESFRI European landmark infrastructure for translational medicine. Joining EATRIS in 2010, he was part of the team responsible for the design and statutory incorporation of the infrastructure, whose membership counts 14 European Members States. In his current role as CEO since 2015, Ussi has a background in technology transfer focused on molecular imaging, with previous history in mechanical engineering and automotive design, and small business administration. He specialises in public-private and public-public collaboration and translational research in medicine. Ussi is also Principle Investigator of REMEDI4ALL, a large EU-funded initiative to develop a European medicines repurposing framework.

<b>Reference: 3.3</b>
<b>European Initiative: ESFRI</b>
<p>The European Strategy Forum on Research Infrastructures , is a strategic instrument to develop the scientific integration of Europe and to strengthen its international outreach. It was established in 2002, with a mandate from the EU Council to support a coherent and strategy-led approach to policy-making on research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better use and development of research infrastructures, at EU and international level. The mission of ESFRI is to support a coherent and strategy-led approach to policy-making on research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better use and development of research infrastructures, at EU and international level. ESFRI's delegates are nominated by the Research Ministers of the Member and Associate Countries, and include a representative of the Commission, working together to develop a joint vision and a common strategy.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Dominik Sobczak</b>
<b>Organisation</b>
European Commission, DG Research and Innovation
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Dominik Sobczak graduated from Warsaw School of Economics in Finance and Banking and in European Studies, where he also worked as a research project manager and a researcher in macroeconomics, financial markets and European integration. After joining the European Commission in 2005 he worked in the area of socio-economic sciences and humanities in DG Research and Innovation, developing the European research agenda in macroeconomics, finance, demography, corporate social responsibility and youth, among others. In 2014 he joined the Research Infrastructures unit as Executive Secretary of the European Strategy Forum on Research Infrastructures (ESFRI), coordinating the support of the European Commission to the Forum and following up the implementation of the ESFRI Roadmap. Since April 2021 he is Deputy Head of Unit for Research and Innovation Actors and Research Careers, continuing his work on research infrastructure policy. He is Commission representatives in a number of ESFRI working groups, including the Strategy Working Group on Health &amp; Food, which is responsible for research infrastructures in life sciences.</p>



<b>Reference: 3.4</b>
<b>European Initiative: EUHA</b>
The European University Hospital Alliance is formed by leading European university hospitals with demonstrated excellence in healthcare, education and research. The vision of the European University Hospital Alliance (EUHA) is to build a network of sustainable healthcare ecosystems in Europe which achieve the best possible quality of care with the resources available. EUHA's strategic plan for 2021-2023 challenges EUHA to 'Lead by Doing'. In these years EUHA will focus on applying the unique role of academic medicine to improve population health and healthcare outcomes, by leading the development of innovative solutions to the most important challenges facing European health and healthcare. EUHA includes a Clinical Trials Working Group
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname
<b>Lynn Seveke</b>


<b>Reference: 3.5</b>
<b>European Initiative: conect4children</b>
conect4children, c4c, pan-European paediatric clinical research network is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population. It is a pioneering opportunity to build capacity for the implementation of multinational paediatric clinical trials whilst ensuring the needs of babies, children, young people and their families are met. It is committed to meeting the needs of paediatric patients thanks to a novel collaboration between the academic and the private sectors, which includes 35 academic and 10 industry partners and around 500 affiliated partners.
Member of the SWG:

Name and Surname
<b>Mark Turner</b>
Organisation
University of Liverpool
Brief CV (the entire profile is expected to take up one page)
Professor Mark Turner BSc, PhD, MBChB, DRCOG, MRCP(UK), FRCPCH, FFPM(Hon) Professor of Neonatology and Research Delivery, University of Liverpool, UK

Mark Turner graduated from Manchester University with a medical degree in 1991 and a PhD in 1999 (placental physiology). He trained in neonatal medicine in the North West of England and has worked as a Consultant Neonatologist in Liverpool since 2005. His research aims to improve the access of newborn babies and children to high quality medicines. This has included studies of dosing, safety, and efficacy of 15 medicines (contributing to writing 5 paediatric investigation plans); excipient kinetics; manipulations of medicines; the assessment of adverse drug reactions; and the value of age-appropriate formulations. He believes that the coherent integration of the design and conduct of clinical trials is key to improving the quality of medicines. He works to develop efficient medicines research infrastructure in Europe and globally as Chair of the European Network for Paediatric Research at the European Medicines Agency (EnprEMA) (2013 – 2019), co-Director of the International Neonatal Consortium and as co-Coordinator of the Collaborative Network for European Clinical Trials For Children (conect4children, c4c). He is a citizen of the UK and of the Republic of Ireland and Visiting Professor of Paediatrics at University College Cork, Ireland, and the University of Ghent, Belgium.

**Reference: 3.6**
**European Initiative: MIRRI-ERIC**

The Microbial Resource Research Infrastructure (MIRRI) is the pan-European distributed Research Infrastructure for the preservation, systematic investigation, provision and valorisation of microbial resources and biodiversity. MIRRI brings together 50+ microbial domain Biological Resource Centres (mBRCs), culture collections and research institutes from ten European countries. MIRRI serves the bioscience and the bioindustry communities by facilitating the access, through a single point, to the broadest range of high-quality microorganisms, their derivatives, associated data and services, with a special focus on the domains of Health & Food, Agro-Food, and Environment & Energy.

Member of the SWG:



Name and Surname

**Luís Miguel Guimarães Soares**

Organisation

Microbial Resource Research Infrastructure - European Research Infrastructure Consortium (MIRRI-ERIC)

Brief CV (the entire profile is expected to take up one page)

Luís Soares is the Executive Director of MIRRI-ERIC, the pan-European distributed Research Infrastructure for the preservation, study, provision and valorisation of microbial resources and biodiversity, with a special focus on the domains of Health & Food, Agro-Food, and Environment & Energy. He represents MIRRI-ERIC in the Life Sciences Research Infrastructure Strategy Board, and in the ERIC Forum. In the past, he has worked for 13 years on cluster and network development, being involved in conceiving, implementing and consolidating the Health Cluster Portugal (HCP), first as Project Manager, then as Director of Studies and Planning, and finally as Chief Strategy

Officer. As appointed/invited expert, he has held several positions in Portuguese and European working groups and networks, namely: Portugal's Delegate to the Health and Food Strategy Working Group, run by the European Strategy Forum on Research Infrastructures (ESFRI); Member of the Portugal in Europe Research and Innovation Network (PERIN); Co-coordinator of the Research & Innovation Agenda on Health and Clinical and Translational Research, run by the Portuguese Foundation for Science and Technology (FCT); Member of the H2020 SC1 Programme Committee, run by the European Commission; Member of the Regional Platform for Smart Specialisation in Life Sciences and Health, and Member of the Norte Regional Innovation Council, run by the Norte Portugal Regional Coordination and Development Commission (CCDR-N); Representative of Portugal in the Board of EATRIS – European Infrastructure for Translational Medicine. in expert panels of European projects, in advisory boards of innovation projects, and in stakeholder panels of projects dedicated to public innovation policies. He also has had numerous participations as Guest Lecturer in post-graduation programmes, and as speaker/moderator in scientific/business events and training programmes. Luís Soares has a Degree in Applied Biology and a PhD in Sciences (Biology), both from the University of Minho.

**Reference: 3.7**
**European Initiative: ERINHA**

ERINHA is a pan-European distributed Research Infrastructure dedicated to the study of high-consequence emerging and re-emerging pathogens. It brings together leading European Bio-Safety Level 4 and complementary (e.g. BSL3) facilities with longstanding experience of research in the field of highly infectious diseases. Such a coordinated approach is vital in a context marked by frequent globalization of infectious diseases with high risk for public health, society and economy. The overarching goal of ERINHA is to provide capacities to conduct projects which are broad in scope, ambition and require a range of capabilities that no single facility or even country can provide on its own.

Member of the SWG:

**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname

**Diana Stepanyan**

**Reference: 3.8**
**European Initiative: EOSC**


European Open Science Cloud (EOSC) Partnership aims to deploy and consolidate by 2030 an open, trusted virtual environment to enable the estimated 2 million European researchers to store, share and reuse research data across borders and disciplines.

Member of the SWG:

**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname

**Ute Gunsenheimer**

<b>Reference: 3.9</b>
<b>European Initiative: Trials@Home</b>
The Trials@Home consortium explores the opportunities of moving clinical trials from the traditional clinic setting to the participant’s immediate surroundings. These so-called Decentralised Clinical Trials (DCTs) make use of new, digital innovations and enable participants to visit a clinical trial centre less frequently, if at all. Trials@Home follows a co-creative multi-stakeholder approach where academic partners, Small and Medium-sized Enterprises (SMEs), private foundations, and EFPIA partners will work together with other stakeholders from across the medical, technological, regulatory, ethical and social aspects of DCTs, with a common goal to develop concrete and practical recommendations, and pilot tools supporting widespread acceptance and use of DCTs in Europe.
Member of the SWG:

Name and Surname
<b>Mira Zuidgeest</b>
Organisation
University Medical Center Utrecht
Brief CV (the entire profile is expected to take up one page)
<p>Mira Zuidgeest, PhD, PharmD, MSc epidemiology Associate Professor, University Medical Center Utrecht, NL</p> <p>Mira Zuidgeest works as an Associate Professor at the Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht. Trained both as pharmacist and epidemiologist and with a PhD in pharmacoepidemiology in the field of paediatric asthma, her current work focuses on clinical trial innovation, both methodological and operational. As academic lead for the IMI Trials@Home project (<a href="http://www.trialsathome.com">www.trialsathome.com</a>), she researches possibilities of centring trials around patients rather than clinical sites by use of innovative technologies (Decentralised Clinical Trials). She is board member of the GetReal Institute (<a href="http://www.getreal-institute.org">www.getreal-institute.org</a>) and led the development of a decision-support tool (<a href="http://www.getrealtrialtool.eu">www.getrealtrialtool.eu</a>) for randomised clinical trials integrated into routine clinical practice (pragmatic trials), to understand methodological and operational consequences of introducing real-world elements in trial design. She is also investigating the possibilities of the new CTR category of low-intervention clinical trials.</p>

**Reference: 3.10**
**European Initiative: COMET**

The COMET Initiative brings together people interested in the development and application of agreed standardised sets of outcomes, known as ‘core outcome sets’ (COS). These sets represent the minimum that should be measured and reported in all clinical trials of a specific condition, but COS are also suitable for use in routine care, clinical audit and research other than randomised trials. You can read the core outcome set/COMET plain language summary [here](#). The existence or use of a core outcome set does not imply that outcomes in a particular study should be restricted to those in the relevant core outcome set. Rather, there is an expectation that the core outcomes will be collected and reported, making it easier for the results of studies to be compared, contrasted and combined as appropriate; while researchers continue to explore other outcomes as well. COMET aims to collate and stimulate relevant resources, both applied and methodological, to facilitate exchange of ideas and information, and to foster methodological research in this area.

Member of the SWG:



Name and Surname

**Paula Williamson**

Organisation

University of Liverpool


Brief CV (the entire profile is expected to take up one page)


Paula Williamson is Professor of Biostatistics at the University of Liverpool. Her research programme has focussed on several aspects of evidence-based medicine (EBM) including clinical trials, meta-analysis, health outcome selection, and reducing waste in research. She was appointed as an NIHR Senior Investigator in 2014, gave the Bradford Hill Lecture in 2017, and was elected Fellow of the Academy of Medical Sciences (AMS) in 2018, and to AMS Council in 2021.

She chaired the MRC Network of Hubs for Trials Methodology Research, 2008-2018, led a successful bid for a new MRC Trials Methodology Research Partnership from 2019, bringing together major organisations and 25 UK universities. She leads an MRC Doctoral Training Programme in Trials Methodology across 12 Research Organisations.


Paula co-founded the global COMET (Core Outcome Measures in Effectiveness Trials) Initiative in 2010, to improve the quality and relevance of health research to decision makers including patients, health professionals, regulators and policymakers. COMET was the winner of the international Cochrane-REWARD prize in 2017 for reducing waste in research. COMET is a finalist in the inaugural 2023 MRC Open Science Impact Prize.

**Reference: 3.11**

<b>European Initiative: ELIXIR</b>
ELIXIR is a Life-Science Infrastructure for Biological Information that unites Europe’s leading life science organisations in managing and safeguarding the increasing volume of data being generated by publicly funded research. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access services that are vital for their research.
Member of the SWG:

Name and Surname
<b>Andrew Smith</b>
Organisation
ELIXIR
Brief CV (the entire profile is expected to take up one page)
<p>Andrew Smith joined ELIXIR in 2011. As Head of External Relations, Andy manages a team responsible for ELIXIR’s communications, industry engagement, international collaboration and socio-economic impact assessment. In addition, Andy is responsible for engagement with existing and prospective Member States of ELIXIR and leads ELIXIR’s engagement with the EU institutions such as the European Commission and other related EU initiatives.</p> <p>Previously he worked in Brussels for the UK Research Office (UKRO), covering various research programme and policy fields, including acting as National Contact Point helpdesks and supporting UK delegations Programme Committees. Prior to this he has held roles in regional government, managing EU Structural Funds, and on education programmes in Slovenia and the Czech Republic.</p>

<b>Reference: 3.12</b>
<b>REMiDi4ALL</b>
<p>REMEDI4ALL is an EU-funded research initiative to drive forward the repurposing of medicines in Europe. The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics.</p> <p>The REMEDI4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement will closely collaborate to make drug repurposing mainstream.</p>
Picture

Name and Surname
<b>Jillian Harrison</b>
Organisation
<b>Belgian Health Care Knowledge Center (KCE) – KCE Trials</b>
European Initiative <b>REMiDi4ALL</b>
<p>The REMEDI4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement will closely collaborate to make drug repurposing mainstream.</p>
Brief CV (the entire profile is expected to take up one page)
<p><b>Jillian Harrison</b> PhD initially did basic research in both academia and industrial settings before moving to clinical research. She has worked for more than 10 years for a large European academic organization performing cancer clinical trials in various roles including coordinating parts of EU funded projects. Since 2016 she has worked for the Belgian Health Care Knowledge Center (KCE) for KCE Trials. KCE Trials is responsible for the selection and funding of large pragmatic randomised clinical trials to provide high quality data for healthcare decision makers. KCE Trials funds national studies, Belgian</p>

participation in international trials and international trials via running joint calls with the Dutch funder ZonMw.  
 KCE Trials participates in European initiatives and International initiatives in clinical trials e.g. CRIGH.  
 Jillian Harrison represents KCE Trials in the drug repurposing project REMiDi4ALL (funders network) and initiatives on reducing research waste.

<b>Reference: 3.13</b>
<b>European Initiative: Trials Methodology Research Partnership TMRP</b>
Picture

Name and Surname
<b>Professor Paula Williamson</b>
Organisation
<b>University of Liverpool</b>
European Initiative
<b>MRC-NIHR Trials Methodology Research Partnership (TMRP)</b>
Brief CV (the entire profile is expected to take up one page)
<p>Paula Williamson is Professor of Biostatistics at the University of Liverpool. Her research programme has focussed on several aspects of evidence-based medicine (EBM) including clinical trials, meta-analysis, health outcome selection, and reducing waste in research. She was appointed as an NIHR Senior Investigator in 2014, gave the Bradford Hill Lecture in 2017, and was elected Fellow of the Academy of Medical Sciences (AMS) in 2018, and to AMS Council in 2021.</p> <p>Paula chaired the MRC Network of Hubs for Trials Methodology Research, 2008-2018, and led a successful bid for a new MRC Trials Methodology Research Partnership from 2019, bringing together major organisations and 25 UK universities.</p> <p>The TMRP partner networks joining the five Hubs within the MRC HTMR Network include:                  The Global Health Network (TGHN)                  Health Research Board - Trials Methodology Research Network (HRB-TMRN)                  Health Data Research UK</p>



UKCRC Registered CTU Network  
UK Trial Managers' Network (UK TMN)

Eight working groups will specialise in specific areas relevant to trial methodology. The TMRP offers an opportunity to build on the achievements of the MRC HTMR Network while exploring new collaborations and avenues to make continued progress in advancing trial methodology, developing capacity and further reducing research waste.

**Reference: 3.14**

**European Initiative: Clinical Research Initiative for Global Health (CRIGH)**

CRIGH aims to optimise clinical research programmes, develop global standards on clinical research, promote the take-up of innovative methodology and technologies, and encourage international cooperation to rapidly and efficiently respond to global health challenges

Picture



Name and Surname

**Øyvind Melien**

Organisation

**Oslo University Hospital and National Center for Drug Shortage and Preparedness in Specialist Healthcare of Norway**

European Initiative **ECRIN**

Brief CV

Øyvind Melien is Chair of the Management Board in Clinical Research Initiative for Global Health (CRIGH). CRIGH is a global network in clinical research encompassing 20 Member and 20 Observer organisations worldwide with ECRIN as Secretariat. Melien is delegate from Norway on behalf of the Norwegian Research Council to the Assembly of Members in ECRIN. He has a medical degree and degree in cell biology from the University of Oslo, PhD in basic pharmacology in the field of molecular mechanisms in cancer from Dept. of Pharmacology, University of Oslo, Norway, and medical specialist in Clinical Pharmacology from Oslo University Hospital. He has experience as Head of Dept. for Clinical Pharmacology at the National Hospital of Norway, including the Clinical Research Unit, Chair of the secretariat for the national system for Health Technology Assessments (HTA) of Norway, Department director at the Norwegian Institute of Public Health and involved in international collaborations in the field of HTA, pharmacology and medical technologies. Melien served as Norwegian representative on the

OECD Working Group on Noncommercial, Multinational Clinical Trials between 2010 and 2013, chairing the subgroup on Education, Training and Patient Involvement. The OECD Working Group was a predecessor for the foundation of CRIGH. He is currently Head of Section for Drug Therapeutics and Safety and Council for HTA at Oslo University Hospital and Head of the National Center for Drug Shortage and Preparedness in Specialist Health Care of Norway.

**Reference: 3.14bis**

**European Initiative: Clinical Research Initiative for Global Health (CRIGH)**

CRIGH aims to optimise clinical research programmes, develop global standards on clinical research, promote the take-up of innovative methodology and technologies, and encourage international cooperation to rapidly and efficiently respond to global health challenges

Picture



Name and Surname

**Nandi Louise Siegfried**

Organisation

**South African Medical Research Council**

European Initiative **ECRIN**

Brief CV

Nandi Siegfried is a Chief Specialist Scientist at the South African Medical Research Council. She has a medical degree from the University of Cape Town and an MPH (Hons) from the University of Sydney, Australia. She holds a specialist Fellowship in the College of Public Health Medicine and was a Nuffield Medical Fellow at the University of Oxford from 2004 to 2007, where she obtained a DPhil in Clinical Epidemiology. Her research expertise includes systematic review methodology, the conduct and quality of clinical trials, and knowledge translation using evidence to inform clinical guidelines and policy. Her role at the SAMRC includes ensuring methodological rigour during trial conduct and promoting interventional research. Earlier research focused on HIV/AIDS but now encompasses both communicable and non-communicable disease and includes issues of public health importance such as alcohol use and climate change. In addition to her SAMRC role, she consults independently in the public health space, including contributing as technical adviser, chair, and methodological facilitator to over 25 World Health Organization Guidelines Development Groups. Nandi served as the South African representative on the OECD Working Group on Non-commercial, Multinational Clinical Trials between 2011 and 2013. She is

currently the SAMRC representative for the Clinical Research Initiative for Global Health. She holds an honorary Associate Professorship at the University of Cape Town Faculty of Health Sciences.